Post-ASCO 2008: Non-Small Cell Lung Cancer Panel

A Panel Discussion among 7 Key Opinion Leaders and 3 Community Oncologists

June 2008

Deliverable: PowerPoint with key findings.

Objectives:

To conduct a panel discussion among oncologists specializing in lung cancer to review data presented at the 2008 American Society of Clinical Oncology (ASCO) annual meeting, including ImClone’s FLEX trial for Erbitux® (cetuximab), and Eli Lilly’s Alimta® (pemetrexed) trial results as maintenance therapy.  Secondary objectives include:

§    Understand current first-, second- and third-line treatment practices for non-small-cell lung cancer (NSCLC) with particular focus on the use of Erbitux ® (cetuximab), Alimta® (pemetrexed), Avastin® (bevacizumab), and Tarceva® (erlotinib)

§    Define the current practices for NSCLC

§    Investigate how current practices have changed in the past 12 months

§    Solicit predictions for therapeutic changes foreseen in the coming 12 months

§    Analyze the results of ImClone’s FLEX trial

§    Describe the possible impact Erbitux could have on the use of Avastin

§    Determine what additional clinical evidence is needed in order to gain FDA approval for Erbitux as first-line therapy for NSCLC

§    Review the potential cost/benefit issues for Erbitux

§    Discuss the Alimta trial results as maintenance therapy and how it might impact overall utilization of the drug

Companies and Products Mentioned in This Report: 

Company

Ticker Symbol

Product(s)

Eli Lilly and Company

LLY

Alimta® (pemetrexed)

ImClone, a wholly-owned subsidiary of Eli Lilly and Company

LLY

Erbitux® (cetuximab),

 

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

 

§    KOL Oncologists specializing NSCLC treatment  

§    Community oncologists who treat patients with NSCLC

§    Board-certified in specialty

§    Attendance at ASCO 2008 preferred

 

Panelists’ Institutions: 

Institution

State

Cedar Sinai Medical Center

CA

Columbia University Medical Center

NY

Dartmouth-Hitchcock Medical Center

NH

Memorial Sloan-Kettering Cancer Center

NY

Ocala Oncology

FL

Olive View-UCLA Medical Center 

CA

Tennessee Oncology PLLC

TN

University of Medicine and Dentistry

NJ

University of Pennsylvania School of Medicine

PA

Wake Forest University School of Medicine

SC

 


Print Abstract

For additional information on this study or to purchase, please call:

Discussion
Oncology
Panel Intelligence, LLC, 150 Cambridgepark Drive, 7th Floor, Cambridge, MA 02140 617 532 5700